CoLucid Pharmaceuticals to Present at the Ladenburg Thalmann 2016 Healthcare Conference
September 26 2016 - 7:00AM
CoLucid Pharmaceuticals, Inc. (Nasdaq:CLCD), a biopharmaceutical
company that is developing lasmiditan oral tablets for the acute
treatment of migraine in adults, with or without aura, announced
today it will provide a corporate overview at the Ladenburg
Thalmann 2016 Healthcare Conference, being held in New York City on
September 27, 2016.
Ladenburg Thalmann 2016
Healthcare Conference |
Date: |
Tuesday, September 27 |
Time: |
11:30am Eastern Time |
Location: |
Sofitel Hotel New York, Odeon
Room |
Webcast: |
http://wsw.com/webcast/ladenburg2/clcd |
|
|
About CoLucid Pharmaceuticals, Inc.CoLucid was
founded in 2005 and is developing lasmiditan oral tablets for the
acute treatment of migraine headaches in adults and intravenous
lasmiditan for the acute treatment of headache pain associated with
migraine in adults in emergency room and other urgent care
settings.
CONTACT
Thomas Mathers
Chief Executive Officer
CoLucid Pharmaceuticals, Inc.
(857) 285-6494
Hans Vitzthum
Managing Director
LifeSci Advisors, LLC.
(212) 915-2568
COLUCID PHARMACEUTICALS, INC. (NASDAQ:CLCD)
Historical Stock Chart
From Mar 2024 to Apr 2024
COLUCID PHARMACEUTICALS, INC. (NASDAQ:CLCD)
Historical Stock Chart
From Apr 2023 to Apr 2024